Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of BioAtla Inc (NASDAQ: BCAB) closed at $0.77 in the last session, down -6.32% from day before closing price of $0.82. In other words, the price has decreased by -$6.32 from its previous closing price. On the day, 1.25 million shares were traded. BCAB stock price reached its highest trading level at $0.8793 during the session, while it also had its lowest trading level at $0.7437.
Ratios:
We take a closer look at BCAB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 0.54 and its Current Ratio is at 0.54.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BCAB now has a Market Capitalization of 45405128 and an Enterprise Value of 43266128.
Stock Price History:
The Beta on a monthly basis for BCAB is 1.01, which has changed by -0.37099236 over the last 52 weeks, in comparison to a change of 0.12838376 over the same period for the S&P500. Over the past 52 weeks, BCAB has reached a high of $1.49, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -3.39%, while the 200-Day Moving Average is calculated to be 48.57%.
Shares Statistics:
According to the various share statistics, BCAB traded on average about 1.39M shares per day over the past 3-months and 973570 shares per day over the past 10 days. A total of 58.79M shares are outstanding, with a floating share count of 44.91M. Insiders hold about 23.92% of the company’s shares, while institutions hold 15.69% stake in the company. Shares short for BCAB as of 1764288000 were 6190599 with a Short Ratio of 4.46, compared to 1761868800 on 4521208. Therefore, it implies a Short% of Shares Outstanding of 6190599 and a Short% of Float of 11.93.
Earnings Estimates
The firm’s stock currently is rated by 1.0 analysts.
Analysts are recommending an EPS of between -$1.08 and -$1.08 for the fiscal current year, implying an average EPS of -$1.08. EPS for the following year is -$0.92, with 1.0 analysts recommending between -$0.92 and -$0.92.
